Brett Ernst
Ophthalmology · Harrisburg, PANPI 1346261765
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 37.7% of the total. Reporting peaked in 2021 at $2,498 and has fallen 99.4% since, to $16 in 2024.
Across 116 payments — averaging $51.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Notal Vision, Inc.$1K
- Ivantis, Inc$563
- Johnson & Johnson Surgical Vision, Inc.$525
- Novartis$252
- Bausch & Lomb, A Division Of Bausch Health US, LLC$179
- plus $1K from 18 others
What the payments were for
- Consulting fees$2,43741%
- Speaking & faculty fees$1,03017%
- Food & beverage$2,38540%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $2,237 |
| Notal Vision, Inc. | 2 | $1,030 |
| Ivantis, Inc | 4 | $563 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $525 |
| Novartis | 14 | $252 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $179 |
| Sun Pharmaceutical Industries Inc. | 9 | $171 |
| Mallinckrodt Hospital Products Inc. | 6 | $166 |
| Aerie Pharmaceuticals, Inc. | 8 | $131 |
| Bausch & Lomb Americas Inc. | 6 | $113 |
| Alcon | 5 | $99 |
| Oyster Point Pharma, Inc. | 5 | $93 |
| Amgen | 1 | $62 |
| Biotissue Holdings Inc. | 2 | $47 |
| Johnson & Johnson Vision Care, Inc. | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Glaukos Corporation | 1 | $32 |
| Akorn Operating Company LLC | 2 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $30 |
| NEW World Medical,inc. | 1 | $27 |
| Rxsight Inc | 1 | $24 |
| Eyepoint US, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,940 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $21,079 |
| LumiganBimatoprost | 31 | $20,611 |
| VyzultaLatanoprostene Bunod | 22 | $9,875 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $5,051 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $3,050 |
| Cyclosporine | 11 | $2,430 |
| Latanoprost | 96 | $1,534 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 71 | $1,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan | $131 | $21,07924 claims |
| AbbVieLumigan | $2,237 | $20,61131 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $113 | $9,87522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Harrisburg
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.